Are weight-loss drugs poised to deliver trillions in economic gains?
Core argument: The share of semaglutide patients taking the drug for weight control rose from under 10% in 2019 to 41.7% by the middle of last year, expanding use beyond its initial type 2 diabetes focus.
While GLP-1s were initially focused on patients with type 2 diabetes, their effectiveness for weight management has seen demand grow outside of their initial treatment purpose. In 2019, fewer than 10% of patients on semaglutide were taking it for weight control. By the middle of last year, that proportion surged to 41.7%. Besides bolstering the pockets of big pharma, the economic potential of GLP-1s comes in its second and third-order impacts. 1 in 8 people worldwide are living with obesity. Alongside those who are overweight, they cost the global economy $2 trillion. Nearly 70 cents in the dollar is due to indirect costs – premature mortality and productivity losses associated with ill health. Without intervention, this impact is expected to double by 2035.




